Published in Cancer Weekly, June 7th, 2005
Findings presented at the annual meeting of the American Society of Clinical Oncology expand on data previously reported in The New England Journal of Medicine (2004;351(8):781-791), according to Veridex, LLC.
Of the 177 patients in the study, 53% of women with five or more CTCs per 7.5 mL of blood prior to therapy were found not to survive a year after initial diagnosis, versus 19% whose blood indicated fewer than five CTCs at the same point. Patients in the study were either about to start...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.